<DOC>
	<DOCNO>NCT00866047</DOCNO>
	<brief_summary>This single-arm , open-label , multicenter , clinical trial evaluate efficacy safety brentuximab vedotin ( SGN-35 ) single agent patient relapse refractory ALCL .</brief_summary>
	<brief_title>A Phase 2 Open Label Trial Brentuximab Vedotin ( SGN-35 ) Systemic Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients relapse refractory systemic ALCL previously receive front line chemotherapy . Documented anaplastic lymphoma kinase ( ALK ) status . Histologicallyconfirmed CD30positive disease ; tissue recent post diagnostic biopsy relapsed/refractory disease must available confirmation CD30 expression via slide tumor block . Fluorodeoxyglucoseavid measurable disease least 1.5 cm document positron emission tomography spiral compute tomography . Received previous autologous stem cell transplant least 12 week ( 3 month ) prior . At US site , patient great equal 12 year age may enrol . At nonUS site , patient must great equal 18 year age . Previous treatment brentuximab vedotin . Previously receive allogeneic transplant . Patients current diagnosis primary cutaneous ALCL ( patient transform systemic ALCL eligible ) . Known cerebral/meningeal disease .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Antigens , CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
	<keyword>monomethyl auristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
</DOC>